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Baseline characteristics

  Characteristic                                                                                       NRTI (N=51)         NNRTI (N=10)        InSTI (N=29)        CCR5 antagonist (N=18)   Total (N=108)
  ---------------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------------ -------------------
  Gender, n (%)                                                                                                                                                                             
   Female                                                                                              17 (33.3%)          3 (30.0%)           10 (34.5%)          1 (5.6%)                 31 (28.7%)
  Mode of HIV Transmission, n (%)                                                                                                                                                           
   IDU                                                                                                 15 (29.4%)          5 (50%)             11 (37.9%)          0                        31 (28.7%)
   Homosexual contacts                                                                                 6 (11%)             1 (10%)             4 (13.8%)           14 (77.8%)               25 (23.1%)
   Heterosexual contacts                                                                               17 (33.3%)          3 (30%)             13 (44.8%)          3 (16.7%)                36 (33.3%)
   Other/Unknown                                                                                       13 (25.5%)          1 (10%)             1 (3.4%)            1 (5.6%)                 16 (17.8%)
  Hepatitis co-infection (HCVAb+ or HBsAg+), n (%)                                                                                                                                          
   yes                                                                                                 158 (29.4%)         3 (30%)             10 (34.5%)          0                        28 (25.9%)
   not tested                                                                                          16 (31.4)           2 (20%)             13 (44.8%)          10 (55.6%)               41 (38%)
   Calendar year of starting dual, median (Q1, Q3)                                                     2011 (2008, 2012)   2011 (2004, 2011)   2012 (2010, 2012)   2012 (2011, 2012)        2011 (2010, 2012)
   Age, years, median (Q1, Q3)                                                                         47 (40, 56)         42 (39, 48)         49 (46, 53)         44 (38, 50)              47 (41, 53)
   CD4+ count at starting dual, cells/µ/L, median (Q1, Q3)                                             420 (294, 650)      712 (306, 884)      455 (282, 678)      610 (530, 640)           486 (305, 701)
   ALT at starting dual, UI/L, median (Q1, Q3)                                                         23 (17, 39)         43 (29, 56)         30 (18, 45)         18 (12, 21)              24 (17, 39)
   AST at starting dual, UI/L, median (Q1, Q3)                                                         23 (15, 43)         41 (28, 83)         28 (21, 53)         23 (19, 29)              27 (19, 46)
  VL at initiation of first ART, n (%)                                                                                                                                                      
   100,000 copies/mL                                                                                   11 (21.6%)          4 (40%)             7 (24.1%)           3 (16.7%)                25 (23.1%)
   \>100,000 copies/mL                                                                                 6 (11.8%)           4 (40%)             2 (6.9%)            3 (16.7%)                15 (13.9%)
   Unknown                                                                                             34 (66.7%)          2 (20%)             20 (69%)            12 (66.7%)               68 (63%)
   Follow-up for composite outcome (VL200 copies/mL or stop/intensification), months, median (Q1, Q3   18 (5, 30)          25 (9, 28)          11 (7, 33)          22 (10, 25)              18 (7, 30)
  Other drug, n (%)                                                                                                                                                                         
   Lamivudine                                                                                          42 (82.4%)          0                   0                   0                        42 (38.9%)
   Emtricitabine                                                                                       3 (5.9%)            0                   0                   0                        3 (2.8%)
   Tenofovir                                                                                           6 (11.8%)           0                   0                   0                        6 (5.6%)
   Efavirenz                                                                                           0                   3 (30)              0                   0                        3 (2.8%)
   Nevirapine                                                                                          0                   6 (60%)             0                   0                        6 (5.6%)
   Etravirine                                                                                          0                   1 (10%)             0                   0                        1 (0.9%)
   Raltegravir                                                                                         0                   0                   29 (100%)           0                        29 (26.9%)
   Maraviroc                                                                                           0                   0                   0                   18 (100%)                18 (16.7%)
   Previously virologically failed a PI, n (%)                                                         6 (11.8%)           2 (20%)             1 (3.4%)            0                        9 (8.3%)
   Time with VL≤50 before switch to dual, months, median (Q1, Q3)                                      7 (1, 50)           38 (14, 60)         5 (2, 14)           7 (3, 19)                7 (2, 26)
   CD4+ nadir, cells/µ/L, median (Q1, Q3)                                                              302 (162, 527)      216 (92, 405)       356 (238, 642)      472 (348, 603)           347 (189, 544)
  CD4+ at time of starting ART, n (%)                                                                                                                                                       
   200 cells/µ/L                                                                                       14 (27.5%)          5 (50%)             7 (24.1%)           2 (11.1%)                28 (25.9%)
   ≥200 cells/µ/L                                                                                      37 (72.5%)          5 (50%)             22 (75.9%)          16 (88.9%)               80 (74.1%)
   eGFR at starting dual, mL/min/1.73m^2^, median (Q1, Q3)                                             82 (68, 109)        94 (59, 113)        78 (54, 102)        104 (93, 113)            88 (66, 110)
   Total-cholesterol at starting dual, mg/dL, median (Q1, Q3)                                          200 (156, 232)      226 (170, 275)      183 (140, 231)      236 (188, 265)           200 (156, 236)
   HDL-cholesterol at starting dual, mg/dL, median (Q1, Q3)                                            44 (37, 52)         54 (47, 80)         48 (37, 60)         44 (37, 50)              45 (37, 57)
   Triglycerides at starting dual, mg/dL, median (Q1, Q3)                                              150 (101, 203)      154 (107, 232)      158 (113, 203)      186 (100, 206)           157 (108, 203)
